Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-α

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 36

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

406

HTML

2277

Tables (1-4)

214

Sum=2897

Sep 28, 2006 (publication date) through Nov 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Sep 28, 2006; 12(36): 5787-5792
Published online Sep 28, 2006. doi: 10.3748/wjg.v12.i36.5787

Table 2 Positive¹ autoantibodies in the two treatment groups before, during and 12 mo after treatment

Group		Before treatment			During treatment			After treatment
	n	LKM²	SMA³	ANA⁴	LKM²	SMA³	ANA⁴	LKM²	SMA³	ANA⁴
IFN-monotherapy	21	1	0	0	2	0	2	1	1	2
IFN /ribavirin-combined treatment	18	0	0	2	0	2	1	0	0	0
Total	39	1	0	2	2	2	3	1	1	2

¹Antibody titer was considered positive at values ≥ 1:40;

²Liver kidney microsomal antibody;

³Anti-smooth muscle antibody;

⁴Antinuclear antibody.

Citation: Gehring S, Kullmer U, Koeppelmann S, Gerner P, Wintermeyer P, Wirth S. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-α. World J Gastroenterol 2006; 12(36): 5787-5792
URL: https://www.wjgnet.com/1007-9327/full/v12/i36/5787.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i36.5787